Why Now & Why PSI?
The resurgence in psychedelic medicine and science over the last 3 decades is disrupting the fields of mental health and neuroscience with multiple clinical trials of psychedelic-assisted therapy showing promise for a wide spectrum of mental health and neuroscience conditions.
However, the recent FDA rejection of MDMA-assisted therapy for PTSD shows that major challenges remain in bringing psychedelic medicines to approval for clinical use.
There is a critical need for expert teams of clinician scientists and mental health care providers experienced in safely delivering psychedelic-assisted therapy and in the rigors of modern-day clinical trial management with controlled substances.
The PSI team is a unique multispecialty group of mental health, psychotherapy and neuroscience experts who have conducted multiple clinical trials of psychedelic medicines for conditions such as depression, anxiety and alcohol use disorder, and conducted over 700 ketamine sessions in the past 5 years.
In 2025, the PSI team will launch their new state-of-the-art clinic in Santa Monica to conduct clinical trials of psychedelic medicines, provide ketamine-assisted psychotherapy and help create an affordable, sustainable and scalable paradigm-shifting model of mental health care.
Next Steps
Our goals
Conduct clinical trials of existing and novel psychedelic medicines for mental health disorders such as major depression, treatment resistant depression, post-partum depression, generalized anxiety disorder, substance use disorders, PTSD and related conditions.
Conduct clinical trials of existing and novel psychedelic medicines for chronic and degenerative neurological conditions such as stroke, TBI, mild cognitive impairment, dementia and pain syndromes.
Provide mental health services including ketamine-assisted psychotherapy and other established psychotherapy services.
Provide education and training in the rapidly evolving fields of psychedelic medicine & science.
Help expand access of psychedelic-based mental health care services to underserved populations.
Years 1 - 3
The primary PSI revenue streams will be from industry-sponsored clinical trials of psychedelic compounds.
Secondary revenue stream will be from ketamine-assisted psychotherapy and other standard psychotherapy services (both insurance covered and cash-pay).
Eventual revenue streams will be from use of psychedelic medicines in PAT as they become FDA-approved or legalized in California.
Act Now
We are seeking to collaborate with like-minded individuals, foundations and family offices who have a strong belief and interest in advancing psychedelic medicines for the betterment of humanity and for specifically impacting mental health and neuroscience conditions for which current treatments are often ineffective.
If you are interested in learning more about PSI and our Psychedelic Innovation Fund or investing in PSI, please contact us.
